Posted by Michael Wonder on 26 Sep 2018
AbbVie receives approval from Health Canada for the combination of Venclexta with rituximab as a treatment for patients with chronic lymphocytic leukaemia
25 September 2018 - In the MURANO Phase 3 clinical trial, the Venclexta (venetoclax) plus rituximab combination showed a significant improvement in progression-free survival for relapsed/refractory chronic lymphocytic leukaemia patients.
AbbVie today announced Health Canada has issued a Notice of Compliance for Venclexta (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy.
